Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers
Catherine Milch(Millennium Engineering and Integration (United States)), Irving H. Fox(Takeda (United States)), Whitney Kent(Takeda (United States)), Joseph R. Berger(University of Pennsylvania), Jing Xu(Soochow University), Tim Wyant(Curis (United States))
Cited by 11
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694